Search research articles
Contact Us
Filters
Showing results (81-90 of 101) with videos related to
Page
of 11
Sort By:
Molecular Cancer Therapeutics
|
November 18, 2021
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Magda Bahcall, Cloud P Paweletz, Yanan Kuang, et al.
British Journal of Haematology
|
January 30, 2013
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
Andrew M Evens, Fangxin Hong, Leo I Gordon, et al.
Urologic Oncology
|
December 23, 2020
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial
Donna L Berry, Fangxin Hong, Traci M Blonquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
The Lancet. Haematology
|
August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Blood
|
February 7, 2013
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
Jennifer A Kanakry, Hailun Li, Lan L Gellert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Frontiers in Immunology
|
June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
Amy K Erbe, Wei Wang, Patrick K Reville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2015
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
Ranjana H Advani, Fangxin Hong, Richard I Fisher, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 101) with videos related to
Sort By:
Page
of 11
Molecular Cancer Therapeutics
|
November 18, 2021
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Magda Bahcall, Cloud P Paweletz, Yanan Kuang, et al.
British Journal of Haematology
|
January 30, 2013
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
Andrew M Evens, Fangxin Hong, Leo I Gordon, et al.
Urologic Oncology
|
December 23, 2020
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial
Donna L Berry, Fangxin Hong, Traci M Blonquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
The Lancet. Haematology
|
August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Blood
|
February 7, 2013
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
Jennifer A Kanakry, Hailun Li, Lan L Gellert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
Amy K Erbe, Wei Wang, Lakeesha Carmichael, et al.
Frontiers in Immunology
|
June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
Amy K Erbe, Wei Wang, Patrick K Reville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2015
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
Ranjana H Advani, Fangxin Hong, Richard I Fisher, et al.
Page
of 11